Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

2.775 -0.035 (-1.25%)

Delayed Quote Updated: 2:16 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adagene Inc. - ADS, each representing 1.25 ordinary shares

< Previous 1 2 3 4 5 Next >

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

January 05, 2023

From Adagene Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 22, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 22, 2022

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday!

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 16, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

March 11, 2022

During Friday's session, 198 companies made new 52-week lows. Key Facts About Today's 52-Week Highs And Lows: Alibaba Group Holding (NYSE:BABA) is the largest...

Via Benzinga

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session ↗

December 16, 2022

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

Via Benzinga

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer

December 16, 2022

From Adagene Inc.

Via GlobeNewswire

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

November 21, 2022

From Adagene Inc.

Via GlobeNewswire

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

November 10, 2022

From Adagene Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 01, 2022

Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!

Via InvestorPlace

Stocks That Hit 52-Week Lows On Tuesday ↗

October 25, 2022

On Tuesday, 120 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 25, 2022

Gainers

Via Benzinga

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November

October 11, 2022

From Adagene Inc.

Via GlobeNewswire

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Aspen Aerogels And 28 Stocks Moving Premarket ↗

June 30, 2022

Gainers

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 02, 2022

Tuesday's session saw 63 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 29, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 17, 2022

Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.

Via Benzinga

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session ↗

June 30, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical...

Via Benzinga

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors ↗

March 16, 2022

Via Benzinga

71 Biggest Movers From Yesterday ↗

June 16, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗

May 05, 2022

The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

March 31, 2022

On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi ↗

March 05, 2022

Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in...

Via Talk Markets

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact ↗

March 02, 2022

Sanofi SA (NASDAQ: SNY) has signed a collaboration with Adagene Inc (NASDAQ: ADAG) to advance two preclinical immuno-oncology candidates and an option to...

Via Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗

March 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

67 Biggest Movers From Yesterday ↗

March 01, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 25, 2022

On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.